Comorbidity of anxiety disorders in major depressive disorder: a clinical trial to evaluate neuropsychological deficit

• Autores: Ixchel Herrera-Guzmán, Esteve Gudayol-Ferré, Adolfo José Jarne Esparcia, Daniel Herrera-Guzmán, Maribel Peró, Joan Guàrdia Olmos, Jorge E. Herrera Abarca
• Localización: European journal of psychiatry, ISSN 0213-6163, Vol. 23, Nº 1, 2009, págs. 5-18
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • Background and objectives: Various clinical aspects of Major Depressive Disorder (MDD) are related to the neuropsychological impairments characteristic of this illness. The aim of this study was to determine the relation between certain clinical variables of MDD - in particular the presence of comorbid anxiety disorders - and the neuropsychological performance of patients with MDD selected for a clinical trial. Methods: Using cluster analyses, we generated two groups of patients: one group with Major Depressive Disorder and a Comorbid Anxiety Disorder (MDDAD), and the other with Pure Major Depressive Disorder (PMDD). Both groups were assessed clinically and neuropsychologically before and after 24 weeks of pharmacological treatment. Neuropsychological performance prior to treatment was comparable in the two groups. Results: After treatment, both groups showed cognitive improvement in attention tasks, memory, and executive functions Conclusions: The PMDD group obtained greater neurocognitive benefits from the antidepressive treatment than the MDDAD group.